Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 5/20 | 0.62 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.62 |
| ▸ | PDE4A | P27815 | 4/20 | 0.62 |
| ▸ | PDE4B | Q07343 | 4/20 | 0.62 |
| ▸ | PDE4C | Q08493 | 4/20 | 0.62 |
| ▸ | PDE4D | Q08499 | 4/20 | 0.62 |
| ▸ | RAB9A | P51151 | 4/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.54 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 2/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7068244 | 0.89 | NPC1 (0.57) | NPC1HSP90AA1PDE4APDE4BPDE4C | |
| SCHEMBL1581300 | 0.84 | KMT2A (0.70) | NPC1HSP90AA1PDE4APDE4BPDE4C | |
| SCHEMBL359110 | 0.83 | PRMT5 (0.60) | NPC1RAB9AKMT2AALDH1A1GAA | |
| SCHEMBL3107502 | 0.80 | PRMT5 (0.56) | NPC1RAB9AKMT2AALDH1A1HTT | |
| SCHEMBL3543581 | 0.80 | PRMT5 (0.59) | NPC1RAB9AALDH1A1GAASMN1; SMN2 | |
| SCHEMBL358780 | 0.79 | ALDH1A1 (0.50) | NPC1HSP90AA1RAB9AKMT2AALDH1A1 | |
| SCHEMBL3539503 | 0.78 | PRMT5 (0.66) | NPC1RAB9AALDH1A1GAASMN1; SMN2 | |
| SCHEMBL309800 | 0.78 | ALDH1A1 (0.53) | NPC1RAB9AKMT2AALDH1A1GAA | |
| SCHEMBL16324795 | 0.76 | ALDH1A1 (0.67) | NPC1HSP90AA1RAB9AKMT2AALDH1A1 | |
| SCHEMBL3549288 | 0.76 | SMN1; SMN2 (0.63) | NPC1RAB9AKMT2AALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030212120-A1 | Compositions comprising a substituted benzimidazole useful for treating immunomediated inflammatory disorders | AXYS PHARMACEUTICALS, INC. (US) | 2003-11-13 | — | — | US | disclosed |
| US-6562854-B2 | Antiinflammatory agents; respiratory system disorders | AXYS PHARMACEUTICALS, INC. | 2003-05-13 | — | — | US | disclosed |
| US-20010053779-A1 | Novel compounds and compositions for treating diseases asociated with protease activity | Celera Corporation | 2001-12-20 | — | — | US | disclosed |
| EP-1019382-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING DISEASES ASSOCIATED WITH SERINE PROTEASE, PARTICULARLY TRYPTASE, ACTIVITY | AXYS PHARMACEUTICALS, INC. (US) | 2000-07-19 | — | — | EP | disclosed |
| WO-1998045275-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING DISEASES ASSOCIATED WITH SERINE PROTEASE, PARTICULARLY TRYPTASE, ACTIVITY | AXYS PHARMACEUTICALS CORPORATION (US) | 1998-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010053779-A1 | Novel compounds and compositions for treating diseases asociated with protease activity | CMA1, CPA3, TPSG1 | NPC1 1362/4885HSP90AA1 4559/4885PDE4A 1106/4885 |
| US-20030212120-A1 | Compositions comprising a substituted benzimidazole useful for treating immunomediated inflammatory disorders | CMA1, TPSG1, TPSD1 | NPC1 3932/4885HSP90AA1 3815/4885PDE4A 1396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.